Use of PAF
AssigneeThe Canadian Red Cross Society
InventorsSofia Hashemi, Douglas Palmer
Life of this patent
Estimating the term…
Abstract
The use of platelet-activating factor (PAF) to increase the levels of von Willebrand factor and/or Factor VIII in blood is disclosed. The use of PAF has particular application in the treatment of von Willebrand disease and haemophilia A.
Claims16
A method for stimulating the release of von Willebrand factor and/or Factor VIII in human cells comprising administering to said human cells a compound selected from the group consisting of platelet activating factor (PAF) having the following formula:
- ##STR2## and an analogue or derivative of PAF having PAF activity in an amount effective to stimulate the release of von Willebrand factor and/or Factor VIII in human cells.
A method for treating von Willebrand disease comprising administering to a subject in need thereof a compound selected from the group consisting of platelet activating factor (PAF) having the following formula:
- ##STR3## and an analogue or derivative of PAF having PAF activity in an amount effective in stimulating the release of von Willebrand factor.
A method of treating hemophilia A comprising administering to a subject in need thereof a compound selected from the group consisting of platelet activating factor (PAP) having the following formula:
- ##STR4## and an analogue or derivative of PAF having PAF activity in an amount effective in stimulating the release of Factor VIII.
A pharmaceutical composition comprising a compound selected from the group consisting of platelet activating factor (PAF) having the following formula:
- ##STR5## and an analogue or derivative of PAF having PAF activity in an amount effective in stimulating the release of von Willebrand factor and/or Factor VIII in human cells, wherein said human cells are exposed to a concentration in the range of about 25 to 300 picomolar of said compound, and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.